DIPL.-BIOL. DR. RER. NAT. D. PAULMANN

C/O DR. BRILL + PARTNER GMBH
INSTITUT FÜR HYGIENE UND MIKROBIOLOGIE
NORDEROOG 2, DE 28259 BREMEN
TELEFON 0049-40/557631-0
TELEFAX 0049-40/557631-11

EMAIL INFO@BRILLHYGIENE.COM
INTERNET WWW.BRILLHYGIENE.COM

DR. D. PAULMANN · C/O DR. BRILL + PARTNER GMBH · NORDEROOG 2 · DE-28259 BREMEN

ROPIMEX R. OPEL GmbH Bildstocker Straße 12 DE – 66538 Neunkirchen

Bremen, 15/04/2020

Statement: Modified vaccinia virus Ankara (MVA) as surrogate virus to confirm virucidal activity against all enveloped viruses

In Europe, the modified vaccinia virus Ankara (MVA) represents the official surrogate test virus for all enveloped viruses. For surface disinfectants it is defined in the EN 14476 (quantitative suspension test for the evaluation of virucidal activity of chemical disinfectants and antiseptics used in human medicine (phase 2/step 1) and the EN 16777 (chemical disinfectants and antiseptics — Quantitative non-porous surface test without mechanical action for the evaluation of virucidal activity of chemical disinfectants used in the medical area — Test method and requirements (phase 2/step 2).

The claim is resulting from the prEN 14885:2020 in combination with the above-mentioned standards where details are given how to use the European standards for making claims. From the table in 4.3.2.6 the conclusion can be drawn that after passing examinations with MVA an activity against all enveloped viruses including members of the virus family *coronaviridae* (like MERS-CoV, SARS-CoV-1 and SARS-CoV-2) is achieved.

Dr. D. Paulmann